Filing Flows

Filing Flows › Bristol Myers Squibb (BMY) › Next earnings date

Bristol Myers Squibb (BMY) earnings: beat the estimate

Bristol Myers Squibb (BMY) reported on Oct 29, 2026 and beat the EPS estimate: $1.35 against $1.17 (+15.2%). Revenue was $13.1B for Q3 2026, +7% year over year. The stock moved +3.2% on the report. It beat the EPS estimate in 100% of the quarters on record.

Last result+15.2% vs estimate
Beat rate100%

The last report

Bristol Myers Squibb reported revenue of $13.1B for the third quarter 2026 (+7% Y/Y), net earnings $2.2B: Net product sales $12.6B, Camzyos $420M. How it makes money → · Every quarter →

Bristol Myers Squibb: EPS against the estimate, last 5 reportsBristol Myers Squibb: EPS against the estimate, last 5 reportsEstimateReported$1.52$1.63Oct 25$1.20$1.26Feb 26$1.42$1.58Apr 26$1.60$2.04Jul 26$1.17$1.35Oct 26
Latest (Oct 26): Estimate $1.17, Reported $1.35.
BMY: the stock's move on each reportBMY: the stock's move on each reportOct 29, 2026+3.2%Jul 30, 2026+3.5%Apr 30, 2026+1.1%Feb 5, 2026+7.6%Oct 30, 2025+8.1%

Bristol Myers Squibb's latest quarter

Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.

Questions

Did Bristol Myers Squibb beat earnings?

Bristol Myers Squibb (BMY) reported on Oct 29, 2026 and beat the EPS estimate: $1.35 against $1.17 (+15.2%).

When does BMY report earnings?

The next date is not set yet.

Does Bristol Myers Squibb usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.